

Introduction

National Center for Health Statistics. Number of deaths involving opioids. Available at: <https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates>. Accessed July 18, 2019.

National Institute on Drug Abuse. Opioid Overdose Crisis. Available at: <https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis>. Accessed July 24, 2019.

Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders. Abstinence, methadone, or buprenorphine-naloxone? *Can Fam Physician* 2017;63:200–5.

Martin SA, Chiodo LM, Bosse JD, Wilson A. The Next Stage of Buprenorphine Care for Opioid Use Disorder. *Ann Intern Med*. 2019 Jun 4;170(11):821-822.

D’Onofrio G, McCormack RP, Hawk K. Emergency Departments - A 24/7/365 Option for Combating the Opioid Crisis. *N Engl J Med*. 2018 Dec 27;379(26):2487-2490.

Martin A, Mitchell A, Wakeman S, White B, Raja A. Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. *Acad Emerg Med*. 2018 May;25(5):601-604.

ACMT 2019. ACMT Position Statement: Buprenorphine Administration in the Emergency Department. Available at: https://www.acmt.net/_Library/Positions/ACMT_Bup_ED_Position_Statement_REV.pdf. Accessed July 24, 2019.

Samet JH, Botticelli M, Bharel M. Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment. *N Engl J Med*. 2018 Jul 5;379(1):7-8.

Raheemullah A, Lembke A. Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment. *JAMA Intern Med*. 2019 Jan 14.

Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. *Lancet*. 2019 Apr 27;393(10182):1760-1772.

Saloner B, Stoller KB, Alexander GC. Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment. *N Engl J Med*. 2018 Jul 5;379(1):4-6.

Volkow ND, Wargo EM. Overdose Prevention Through Medical Treatment of Opioid Use Disorders. *Ann Intern Med*. 2018 Aug 7;169(3):190-192.

Wakeman SE, Barnett ML. Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities. *N Engl J Med*. 2018 Jul 5;379(1):1-4.

Preventing OUD (Q1)

Weiner SG, Baker O, Rodgers AF, Garner C, Nelson LS, Kreiner PW, Schuur JD. Opioid Prescriptions by Specialty in Ohio, 2010-2014. *Pain Med*. 2018 May 1;19(5):978-989.

Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. *MMWR Morb Mortal Wkly Rep*. 2017 Mar 17;66(10):265-269.

Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: a retrospective cohort study. *Arch Intern Med*. 2012 Mar 12;172(5):425-30.

Barnett ML, Olenski AR, Jena AB. Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use. *N Engl J Med*. 2017 Feb 16;376(7):663-673.

Beaudoin FL, Gutman R, Merchant RC, Clark MA, Swor RA, Jones JS, Lee DC, Peak DA, Domeier RM, Rathlev NK, McLean SA. Persistent pain after motor vehicle collision: comparative effectiveness of opioids vs nonsteroidal antiinflammatory drugs prescribed from the emergency department—a propensity matched analysis. *Pain*. 2017 Feb;158(2):289-295.

Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. *BMJ*. 2018;360:j5790. Published 2018 Jan 17.

Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use. *J Gen Intern Med*. 2016 May;31(5):478-85.

Delgado MK, Huang Y, Meisel Z, Hennessy S, Yokell M, Polsky D, Perrone J. National Variation in Opioid Prescribing and Risk of Prolonged Use for Opioid-Naive Patients Treated in the Emergency Department for Ankle Sprains. *Ann Emerg Med*. 2018 Oct;72(4):389-400.e1.

Deyo RA, Hallvik SE, Hildebran C, Marino M, Dexter E, Irvine JM, O’Kane N, Van Otterloo J, Wright DA, Leichtling G, Millet LM. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study. *J Gen Intern Med*. 2017 Jan;32(1):21-27.

Harbaugh CM, Lee JS, Hu HM, McCabe SE, Voepel-Lewis T, Englesbe MJ, Brummett CM, Waljee JF. Persistent Opioid Use Among Pediatric Patients After Surgery. *Pediatrics*. 2018 Jan;141(1):e20172439.

Hoppe JA, Kim H, Heard K. Association of emergency department opioid initiation with recurrent opioid use. *Ann Emerg Med*. 2015 May;65(5):493-499.e4.

Johnson SP, Chung KC, Zhong L, Shauver MJ, Engelsbe MJ, Brummett C, Waljee JF. Risk of Prolonged Opioid Use Among Opioid-Naive Patients Following Common Hand Surgery Procedures. *J Hand Surg Am*. 2016 Oct;41(10):947-957.e3.

Schroeder AR, Dehghan M, Newman TB, Bentley JP, Park KT. Association of Opioid Prescriptions From Dental Clinicians for US Adolescents and Young Adults With Subsequent Opioid Use and Abuse. *JAMA Intern Med*. 2019 Feb 1;179(2):145-152.

Nelson LS, Juurlink DN, Perrone J. Addressing the Opioid Epidemic. *JAMA*. 2015 Oct 13;314(14):1453-4.

Strayer RJ, Motov SM, Nelson LS. Something for pain: Responsible opioid use in emergency medicine. *Am J Emerg Med*. 2017 Feb;35(2):337-341.

Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. *J Med Toxicol*. 2012 Dec;8(4):335-40.

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States. *Pain*. 2013 Dec;154(12):2639-48.

Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *MMWR Recomm Rep*. 2016 Mar 18;65(1):1-49.

Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, Gagnon DR. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. *JAMA Intern Med*. 2015 Apr;175(4):608-15.

Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med*. 2004 Dec 30;351(27):2827-31.

Tobias JD, Green TP, Coté CJ; SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE; COMMITTEE ON DRUGS. Codeine: Time to Say “No”. *Pediatrics*. 2016 Oct;138(4):e20162396.

Young JW, Juurlink DN. Tramadol. CMAJ. 2013 May 14;185(8):E352.

Nelson LS, Juurlink DN. Tramadol and hypoglycemia: one more thing to worry about. JAMA Intern Med. 2015 Feb;175(2):194-5.

Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9):872-882.

Dionne RA, Gordon SM, Moore PA. Prescribing Opioid Analgesics for Acute Dental Pain: Time to Change Clinical Practices in Response to Evidence and Misperceptions. Compend Contin Educ Dent. 2016 Jun;37(6):372-378;quiz379.

Patel NA, Afshar S. Addressing the high rate of opioid prescriptions for dental pain in the emergency department. Am J Emerg Med. 2018 Jan;36(1):138-139.

Levin M. Opioids in headache. Headache. 2014 Jan;54(1):12-21.

Franklin GM; American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014 Sep 30;83(14):1277-84.

Drug Enforcement Agency. Controlled Substance Public Disposal Location Search Utility. Available at: <https://apps2.deadiversion.usdoj.gov/pubdispsrch/spring/main?execution=e1s1>. Accessed July 24, 2019.

US Food and Drug Administration. Disposal of Unused Medicines: What You Should Know. Available at: <https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know>. Accessed July 24, 2019.

Management of Opioid Withdrawal (Q2, Q3, Q4)

Wightman RS, Nelson LS, Lee JD, Fox LM, Smith SW. Severe opioid withdrawal precipitated by Vivitrol®. Am J Emerg Med. 2018 Jun;36(6):1128.e1-1128.e2.

Surmaitis RM, Khalid MM, Vearrier D, Greenberg MI. Takotsubo cardiomyopathy associated with buprenorphine precipitated withdrawal. Clin Toxicol (Phila). 2018 Sep;56(9):863-864.

Su MK, Lopez JH, Crossa A, Hoffman RS. Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome. Am J Emerg Med. 2018 Nov;36(11):1951-1956.

Juurlink DN. Lofexidine for Opioid Withdrawal: Small Effects at an Exorbitant Price. J Addict Med. 2019 May/June;13(3):167-168.

Harm Reduction (Q5)

Vivolo-Kantor AM, Seth P, Gladden RM, et al. Vital Signs : Trends in Emergency Department Visits for Suspected Opioid Overdoses — United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep 2018;67(9):279–85.

Weiner SG, Baker O, Bernson D, Schuur JD. One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose. Ann Emerg Med 2019;

Hawk KF, Vaca FE, D’Onofrio G. Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies. Yale J Biol Med 2015;88(3):235–45.

Adams JM. Increasing Naloxone Awareness and Use. JAMA 2018;319(20):2073.

Samuels EA, Dwyer K, Mello MJ, Baird J, Kellogg A, Bernstein E. Emergency Department-Based Opioid Harm Reduction: moving physicians from willing to doing. Acad Emerg Med 2016;23(4):455–65.

Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005 Jun;82(2):303–311.

Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy. 2010 May;21(3):186–193.

Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346:f174.

Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol 2014;43(1):235–48.

The Henry J. Kaiser Family Foundation. Sterile Syringe Exchange Programs Available at: <https://www.kff.org/hiv/aids/state-indicator/syringe-exchange-programs>. Accessed July 1, 2019.

Centers for Disease Control and Prevention. Syringe Services Programs. Available at: <https://www.cdc.gov/hiv/risk/ssps.html>. Accessed on July 1, 2019.

Health and Human Services Department. Determination That a Demonstration Needle Exchange Program Would be Effective in Reducing Drug Abuse and the Risk of Acquired Immune Deficiency Syndrome Infection Among Intravenous Drug Users. Available at: <https://www.federalregister.gov/documents/2011/02/23/2011-3990/determination-that-a-demonstration-needle-exchange-program-would-be-effective-in-reducing-drug-abuse>. Accessed on July 1, 2019.

Kishore S, Hayden M, Rich J. Lessons from Scott County — Progress or Paralysis on Harm Reduction? N Engl J Med 2019;380(21):1988–90.

Gostin LO, Hodge JG Jr, Gulinson CL. Supervised Injection Facilities: Legal and Policy Reforms. JAMA. 2019 Feb 7;10.1001/jama.2019.0095.

American Medical Association 2017. AMA wants new approaches to combat synthetic and injectable drugs. Available at: <https://www.ama-assn.org/press-center/press-releases/ama-wants-new-approaches-combat-synthetic-and-injectable-drugs>. Accessed July 6, 2019.

New York City Department of Health 2019. Guidance for the Care of Patients Presenting to New York City Emergency Departments Following a Non-Fatal Opioid Overdose. <https://www1.nyc.gov/assets/doh/downloads/pdf/basas/non-fatal-overdose-providers.pdf>. Accessed July 4, 2019.

Treatment Options (Q6, Q7)

Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction. J Addict Med. 2016 Mar-Apr;10(2):93-103.

Sofuoglu M, DeVito EE, Carroll KM. Pharmacological and behavioral treatment of opioid use disorder. Psychiatric Research and Clinical Practice. 2018 Dec 5:appi-prcp.

Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Database Syst Rev.* 2011;(10):CD004147. Published 2011 Oct 5.

Substance Abuse and Mental Health Services Administration. Medication and Counseling Treatment. Available at: www.samhsa.gov/medication-assisted-treatment/treatment. Accessed July 24, 2019.

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev.* 2014;(2):CD002207. Published 2014 Feb 6.

Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. *Drug and alcohol dependence.* 2019 Jul 1;200:34-9.

Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. *Ann Intern Med.* 2018;169(3):137–145.

Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. *Addiction.* 2016;111(2):298–308.

Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ.* 2017;357:j1550. Published 2017 Apr 26.

Weiss RD, Rao V. The Prescription Opioid Addiction Treatment Study: What have we learned. *Drug Alcohol Depend.* 2017;173 Suppl 1:S48–S54.

Buprenorphine Pharmacology (Q8, Q9)

Coe MA, Lofwall MR, Walsh SL. Buprenorphine Pharmacology Review. *J Addict Med.* October 2018:1-11.

Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. *Arch Gen Psychiatry.* 1978;35(4):501-516.

Huestis M.A. (2002) Controlled Drug Administration Studies of High-Dose Buprenorphine in Humans. In: Kintz P., Marquet P. (eds) *Buprenorphine Therapy of Opiate Addiction.* Forensic Science and Medicine. Humana Press, Totowa, NJ

Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. *Clin Pharmacol Ther.* 1988;44(3):335-342.

Seldén T, Ahlner J, Druid H, Kronstrand R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. *Forensic Sci Int.* 2012;220(1-3):284-290.

Kriikku P, Häkkinen M, Ojanperä I. High buprenorphine-related mortality is persistent in Finland. *Forensic Sci Int.* 2018 Oct;291:76-82.

Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. *Pediatrics.* 2008 Apr;121(4):e782-6.

Athanasos P, Ling W, Bochner F, White JM, Somogyi AA. Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. *Pain Med.* 2019 Jan 1;20(1):119-128.

Buprenorphine Preparations (Q10, Q11, Q12, Q13)

Buprenorphine. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: <http://online.lexi.com>. Accessed February 21, 2019.

Gunderson EW, Hjelmström P, Sumner M, et al. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial. *Clin Ther* 2015;37(10):2244-55.

Gunderson EW, Sumner M. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film. *J Addict Med* 2016;10(2):124-30.

Sullivan JG, Webster L. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study. *Clin Ther* 2015;37(5):1064-75.

Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. *Clin Pharmacol Ther* 1988;44(3):335-42.

Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo InterSERT di Collaborazione Scientifica (GICS). Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. *Eur Addict Res.* 2019;25(1):10-19.

FDA News Release. FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence, 2018. Available at: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm610807.htm>. Accessed November 29, 2018.

Voelker R. Generic for Opioid Use Disorder. *JAMA* 2018;320(3):228.

University of Buffalo. In Buffalo emergency departments, a better way to treat opioid use disorder. Available at: <http://www.buffalo.edu/news/releases/2018/11/012.html>. Accessed July 24, 2019.

Dhawan A, Modak T, Sarkar S. Transdermal buprenorphine patch: Potential for role in management of opioid dependence. *Asian J Psychiatr.* 2019 Feb;40:88-91.

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med* 2015;9(5):358-367.

ACOG Committee on Obstetric Practice. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. *Obstet Gynecol* 2017;130(2):e81-e94.

Soyka M. Buprenorphine Use in Pregnant Opioid Users: A Critical Review. *CNS Drugs* 2013;27(8):653-62.

Debelak K, Morrone WR, O'Grady, KE, et al. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. *Am J Addict* 2013;22(3):252-4.

Lund IO, Fischer G, Welle-Strand GK, et al. A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. *Subst Abuse* 2013;7:61-74.

Wiegand SL, Stringer EM, Stuebe AM, et al. Buprenorphine and naloxone compared with methadone treatment in pregnancy. *Obstet Gynecol* 2015;125(2):363-8.

Jumah NA, Edwards C, Balfour-Boehm J, et al. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. *BMJ Open* 2016;6(10):e011774.

Nguyen L, Lander LR, O'Grady KE, et al. Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure. *Am J Addict* 2018;27(2):92-6.

Nechanska B, et al. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. *Addiction* 2018;113(7):1286-94.

Fernandez S, Bruni T, Bishop L, Turuba R, Olibris B, Jumah NA. Differences in hospital length of stay between neonates exposed to buprenorphine versus methadone in utero: A retrospective chart review. *Paediatr Child Health*. 2019 May;24(2):e104-e110.

Wong J, Saver B, Scanlan JM, et al. Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome? *J Addict Med* 2018;12(6):435-41.

Resources Required to Use Bup in the ED (Q14, Q15, Q16, Q17)

Substance Abuse and Mental Health Services Administration. Special Circumstances for Prescribing Buprenorphine. Available at: <https://www.samhsa.gov/medication-assisted-treatment/legislation-regulations-guidelines/special>. Accessed July 24, 2019.

Fiscella K, Wakeman SE, Beletsky L. Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver. *JAMA Psychiatry*. 2018 Dec 26;10.1001/jamapsychiatry.2018.3685.

Frank JW, Wakeman SE, Gordon AJ. No end to the crisis without an end to the waiver. *Subst Abus*. 2018;39(3):263-265.

New York Times Editorial Board, 2019. Want to Reduce Opioid Deaths? Get People the Medications They Need. Available at: <https://nyti.ms/2UY6HUz>. Accessed July 24, 2019.

ACMT 2019a. The American College of Medical Toxicology Strongly Recommends Removing Waiver for Prescribing Buprenorphine Available at: https://www.acmt.net/cgi/page.cgi/_zine.html/Press_Releases/ACMT_Strongly_Recommends_Removing_Waiver_for_Prescribing_Buprenorphine_-_Released_July_2019. Accessed Aug 22, 2019.

US Department of Health and Human Services, 2018. Telemedicine and Prescribing Buprenorphine for the Treatment of Opioid Use Disorder. Available at: <https://www.hhs.gov/opioids/sites/default/files/2018-09/hhs-telemedicine-hhs-statement-final-508compliant.pdf>. Accessed July 24, 2019.

The National Alliances of Advocates for Buprenorphine Treatment. DATA-2000 with Amendments. Available at: <http://www.naabt.org/data2000.cfm>. Accessed July 24, 2019.

Centers for Disease Control and Prevention. Assessing and Addressing Opioid Use Disorder. Available at: <https://www.cdc.gov/drugoverdose/training/oud/accessible/index.html>. Accessed July 24, 2019.

Patient Selection for Bup Initiation (Q18, Q19, Q20, Q21)

Martin A, Mitchell A, Wakeman S, White B, Raja A. Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. *Acad Emerg Med*. 2018 May;25(5):601-604.

Duber HC, Barata IA, Cioè-Peña E, Liang SY, Ketcham E, Macias-Konstantopoulos W, Ryan SA, Stavros M, Whiteside LK. Identification, Management, and Transition of Care for Patients With Opioid Use Disorder in the Emergency Department. *Ann Emerg Med*. 2018 Oct;72(4):420-431.

Chalmers CE, Mullinax S, Brennan J, Vilke GM, Oliveto AH, Wilson MP. Screening Tools Validated in the Outpatient Pain Management Setting Poorly Predict Opioid Misuse in the Emergency Department: A Pilot Study. *J Emerg Med*. 2019 Jun;56(6):601-610.

Sahota PK, Shastry S, Mukamel DB, Murphy L, Yang N, Lotfipour S, Chakravarthy B. Screening emergency department patients for opioid drug use: A qualitative systematic review. *Addict Behav*. 2018 Oct;85:139-146.

Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. *Arch Intern Med*. 2010;170(13):1155-60.

Hawk K, D'Onofrio G. Emergency department screening and interventions for substance use disorders. *Addict Sci Clin Pract*. 2018 Aug 6;13(1):18.

ED Initiation of Buprenorphine (Q22, Q23, Q24, Q25, Q26, Q27)

Herring AA, Perrone J, Nelson LS. Managing Opioid Withdrawal in the Emergency Department With Buprenorphine. *Ann Emerg Med*. 2019 May;73(5):481-487.

Kutz I, Reznik V. Rapid heroin detoxification using a single high dose of buprenorphine. *J Psychoactive Drugs*. 2001 Apr-Jun;33(2):191-3.

Ahmadi J. Instant detoxification of heroin with high dose of buprenorphine. *J Addict Prev*. 2016;4(1):3.

Ang-Lee K, Oreskovich MR, Saxon AJ, Jaffe C, Meredith C, Ellis ML, Malte CA, Knox PC. Single dose of 24 milligrams of buprenorphine for heroin detoxification: an open-label study of five inpatients. *J Psychoactive Drugs*. 2006 Dec;38(4):505-12.

Ahmadi J, Jahromi MS, Ghahremani D, London ED. Single high-dose buprenorphine for opioid craving during withdrawal. *Trials*. 2018 Dec 10;19(1):675.

Dunkley CA, Carpenter JE, Murray BP, Sizemore E, Wheatley M, Morgan BW, Moran TP, Steck A. Retrospective Review of a Novel Approach to Buprenorphine Induction in the Emergency Department. *J Emerg Med*. 2019 May 3;50736-4679(19)30236-7.

Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dürsteler KM, Vogel M. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. *Subst Abuse Rehabil*. 2016 Jul 20;7:99-105.

Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series. *Am J Addict*. 2019 Mar 22.

Kornfeld H, Reetz H. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans. *Am J Ther*. 2015 May-Jun;22(3):199-205.

Raheemullah A, Lembke A. Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment. *JAMA Intern Med*. 2019 [Epub ahead of print]. PubMed PMID: 30640372.

Discharge Planning and Prescribing (Q28, Q29, Q30, Q31, Q32, Q33, Q34)

D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. *JAMA*. 2015 Apr 28;313(16):1636-44.

D'Onofrio G, Chawarski MC, O'Connor PG, Pantalon MV, Busch SH, Owens PH, Hawk K, Bernstein SL, Fiellin DA. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. *J Gen Intern Med.* 2017 Jun;32(6):660-666.

Duber HC, Barata IA, Cioè-Peña E, Liang SY, Ketcham E, Macias-Konstantopoulos W, Ryan SA, Stavros M, Whiteside LK. Identification, Management, and Transition of Care for Patients With Opioid Use Disorder in the Emergency Department. *Ann Emerg Med.* 2018 Oct;72(4):420-431.

Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. *Drug Alcohol Depend.* 2018 Dec 1;193:117-123.

Carroll JJ, Rich JD, Green TC. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible. *J Addict Med.* 2018 Nov/Dec;12(6):459-465.

Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, Klinker L, Shaffer HJ. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. *J Subst Abuse Treat.* 2010 Jul;39(1):41-50.

Doernberg M BA, Krawczyk N BA, Agus D JD, Fingerhood M MD. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis? *Subst Abuse.* 2019 Apr 22;1-6.

Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. *Mayo Clin Proc.* 2008 May;83(5):529-35.

Waye KM, Goyer J, Dettor D, Mahoney L, Samuels EA, Yedinak JL, Marshall BDL. Implementing peer recovery services for overdose prevention in Rhode Island: An examination of two outreach-based approaches. *Addict Behav.* 2019 Feb;89:85-91.

Jack HE, Oller D, Kelly J, Magidson JF, Wakeman SE. Addressing substance use disorder in primary care: The role, integration, and impact of recovery coaches. *Subst Abuse.* 2017;39(3):307-314.

Martin A, Mitchell A, Wakeman S, White B, Raja A. Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. *Acad Emerg Med.* 2018 May;25(5):601-604.

Weiner SG, Price CN, Atalay AJ, Harry EM, Pabo EA, Patel R, Suzuki J, Anderson S, Ashley SW, Kachalia A. A Health System-Wide Initiative to Decrease Opioid-Related Morbidity and Mortality. *Jt Comm J Qual Patient Saf.* 2019 Jan;45(1):3-13.

Low Threshold Buprenorphine (Q35, Q36, Q37, Q38)

Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, Garment A, Goldfeld K, Gourevitch MN, Lee JD. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. *Addict Sci Clin Pract.* 2017 Feb 28;12(1):7.

Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P. The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting. *Eur Addict Res.* 2018;24(6):286-292.

Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. *Clin Pharmacol Ther.* 1994 May;55(5):569-80.

Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. *J Clin Psychopharmacol.* 2004 Oct;24(5):479-87.

Foster B, Twycross R, Mihalyo M, Wilcock A. Buprenorphine. *J Pain Symptom Manage.* 2013 May;45(5):939-49.

Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. *Cochrane Database Syst Rev.* 2017 Feb 21;2:CD002025.

Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. *Addiction.* 2005 Dec;100(12):1860-7.

White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. *Drug Alcohol Depend.* 2001 Dec 1;65(1):77-83.

Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. *Drug Alcohol Depend.* 2010 Apr 1;108(1-2):110-4.

Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. *Addict Sci Clin Pract.* 2019 May 6;14(1):20.

Sigmon SC, Ochalek TA, Meyer AC, Hruska B, Heil SH, Badger GJ, Rose G, Brooklyn JR, Schwartz RP, Moore BA, Higgins ST. Interim Buprenorphine vs. Waiting List for Opioid Dependence. *N Engl J Med.* 2016 Dec 22;375(25):2504-2505.

Streck JM, Ochalek TA, Badger GJ, Sigmon SC. Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms. *Exp Clin Psychopharmacol.* 2018 Aug;26(4):403-409.

Martin SA, Chiodo LM, Bosse JD, Wilson A. The Next Stage of Buprenorphine Care for Opioid Use Disorder. *Ann Intern Med.* 2018 Nov 6;169(9):628-635.

Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, Millar T. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. *Addiction.* 2016 Feb;111(2):298-308.

Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Database Syst Rev.* 2011 Oct 5;(10):CD004147.

US Food & Drug Administration. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications>. Accessed July 24, 2019.

Cunningham CO, Roose RJ, Starrels JL, Giovanniello A, Sohler NL. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. *J Addict Med.* 2013 Jul-Aug;7(4):287-93.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ.* 2017 Apr 26;357:j1550.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch Gen Psychiatry.* 2011 Dec;68(12):1238-46.

Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Available at: <https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document-Including-Executive-Summary-and-Parts-1-5-/SMA19-5063FULLDOC>. Accessed July 24, 2019.

Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. *Drug Alcohol Depend*. 2015; 150:112-9.

Buprenorphine-Precipitated Withdrawal (Q39)

Strain EC, Preston KL, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. *J Pharmacol Exp Ther*. 1995 Feb;272(2):628-38.

Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. *J Subst Abuse Treat*. 2010;39(1):51-57.

Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA; American Society Of Addiction Medicine. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. *J Addict Med*. 2011 Dec;5(4):254-63.

Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. *J Clin Psychopharmacol*. 2004 Oct;24(5):479-87.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. *J Clin Pharmacol*. 2006 Feb;46(2):179-92.

Naloxone-Precipitated Withdrawal (Q40)

Herring AA, Perrone J, Nelson LS. Managing Opioid Withdrawal in the Emergency Department With Buprenorphine. *Ann Emerg Med*. January 2019.

Jovaisa T, Laurinen G, Vosylius S, Sipylaite J, Badaras R, Ivaskевичius J. Effects of ketamine on precipitated opiate withdrawal. *Medicina (Kaunas)*. 2006;42(8):625-34.

Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. *Front Psychiatry*. 2018 Jul 24;9:277.

Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review. *Expert Opin Drug Saf*. 2015 Jul;14(7):1137-46.

Rosen MI, McMahon TJ, Hameedi FA, et al. Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. *J Pharmacol Exp Ther*. 1996;276(3):1128-1135.

Walsh SL, Strain EC, Bigelow GE. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. *Addiction*. 2003;98(4):427-439.

Albertson TE, Chenoweth J, Ford J, Owen K, Sutter ME. Is it prime time for alpha2-adrenoceptor agonists in the treatment of withdrawal syndromes? *J Med Toxicol*. 2014 Dec;10(4):369-81.

Neale J, Strang J. Naloxone--does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. *Addiction*. 2015;110(10):1644-1652.

Herring AA, Schultz CW, Yang E, Greenwalk M. Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder. *American Journal of Emergency Medicine*. 2019, ePub before print.

Urban V, Sullivan R. Buprenorphine rescue from naltrexone-induced opioid withdrawal during relatively rapid detoxification from high-dose methadone: a novel approach. *Psychiatry (Edgmont)*. 2008;5(4):56-58.

Phillips RH, Salzman M, Haroz R, Rafeq R, Mazzarelli AJ, Pelletier-Bui A. Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder. *Ann Emerg Med*. 2019 Feb 14;S0196-0644(19)30006-X.

ED Use of PDMPs (Q41)

The Pew Charitable Trusts, 2016. Prescription drug monitoring programs. Evidence-based practices to optimize prescriber use. Available at: https://www.pewtrusts.org/-/media/assets/2016/12/prescription_drug_monitoring_programs.pdf. Accessed July 24, 2019.

National Alliance for Model State Drug Laws, 2017. Established and optional prescription drug monitoring programs. Available at: <https://namsdl.org/wp-content/uploads/Established-and-Operational-Prescription-Drug-Monitoring-Programs-PMPs-%E2%80%93-Map.pdf>. Accessed July 24, 2019.

Griggs CA, Weiner SG, Feldman JA. Prescription drug monitoring programs: examining limitations and future approaches. *West J Emerg Med*. 2015 Jan;16(1):67-70.

Haffajee RL, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. *JAMA*. 2015 Mar 3;313(9):891-2.

National Alliance for Model State Drug Laws, 2019. Mandated use of prescription drug monitoring programs. Available at: <https://namsdl.org/wp-content/uploads/Prescriber-Mandated-Use-of-PDMPs-Map.pdf>. Accessed July 24, 2019.

Weiner SG, Griggs CA, Mitchell PM, Langlois BK, Friedman FD, Moore RL, Lin SC, Nelson KP, Feldman JA. Clinician impression versus prescription drug monitoring program criteria in the assessment of drug-seeking behavior in the emergency department. *Ann Emerg Med*. 2013 Oct;62(4):281-9.

Sun BC, Charlesworth CJ, Lupulescu-Mann N, Young JJ, Kim H, Hartung DM, Deyo RA, McConnell KJ. Effect of Automated Prescription Drug Monitoring Program Queries on Emergency Department Opioid Prescribing. *Ann Emerg Med*. 2018 Mar;71(3):337-347.e6.

McAllister MW, Aaronson P, Spillane J, Schreiber M, Baroso G, Kraemer D, Smotherman C, Gray-Eurom K. Impact of prescription drug-monitoring program on controlled substance prescribing in the ED. *Am J Emerg Med*. 2015 Jun;33(6):781-5.

Khobrani M, Perona S, Patanwala AE. Effect of a legislative mandate on opioid prescribing for back pain in the emergency department. *Am J Emerg Med*. 2019 Feb 22;S0735-6757(19)30117-2.

Hoppe JA, Weiner, SG. Emergency physician interpretation of prescription drug monitoring program profiles. *Acad Emerg Med*. 2015 Mar;22(S1):S16-S17.

Hoppe J, Perrone J, Nelson LS. Being judge and jury: a new skill for emergency physicians. *Ann Emerg Med*. 2013 Oct;62(4):290-2.

Huizenga JE, Breneman BC, Patel VR, Raz A, Speights DB, 2016. NARxCHECK score as a predictor of unintentional overdose death. Available at: <https://apprishealth.com/wp-content/uploads/sites/2/2017/02/NARxCHECK-Score-as-a-Predictor.pdf>. Accessed July 24, 2019.

Hawk K, D'Onofrio G, Fiellin DA, Chawarski MC, O'Connor PG, Owens PH, Pantalon MV, Bernstein SL. Past-year prescription drug monitoring program opioid prescriptions and self-reported opioid use in an emergency department population with opioid use disorder. *Acad Emerg Med*. 2018 May;25(5):508-516.

Marco CA, Venkat A, Baker EF, Jesus JE, Geiderman JM; ACEP Ethics Committee. Prescription Drug Monitoring Programs: Ethical Issues in the Emergency Department. *Ann Emerg Med.* 2016 Nov;68(5):589-598.

Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. *MMWR Morb Mortal Wkly Rep.* 2017 Mar 17;66(10):265-269.

Nelson LS, Juurlink DN, Perrone J. Addressing the Opioid Epidemic. *JAMA.* 2015 Oct 13;314(14):1453-4.

Management of Acute Pain in Bup Patients (Q42)

Ahern TL, Herring AA, Miller S, Frazee BW. Low-Dose Ketamine Infusion for Emergency Department Patients with Severe Pain. *Pain Med.* 2015 Jul;16(7):1402-9.

Karlow N, Schlaepfer CH, Stoll CRT, Doering M, Carpenter CR, Colditz GA, Motov S, Miller J, Schwarz ES. A Systematic Review and Meta-analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department. *Acad Emerg Med.* 2018 Oct;25(10):1086-1097.

Lyon RF, Schwan C, Zeal J, Kharod C, Staak B, Petersen C, Rush SC. Successful Use of Ketamine as a Prehospital Analgesic by Paramedics During Operation Enduring Freedom. *J Spec Oper Med.* 2018 Spring;18(1):70-73.

Childers JW, Arnold RM. Treatment of pain in patients taking buprenorphine for opioid addiction #221. *J Palliat Med.* 2012 May;15(5):613-4.

Sen S, Arulkumar S, Cornett EM, Gayle JA, Flower RR, Fox CJ, Kaye AD. New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine. *Curr Pain Headache Rep.* 2016 Mar;20(3):16.

Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Tompkins DA. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals. *Anesthesiology.* 2019 Jan;130(1):131-141.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial. *JAMA Psychiatry.* 2016 May 1;73(5):447-55.

Quaye AN, Zhang Y. Perioperative Management of Buprenorphine: Solving the Conundrum. *Pain Med.* 2018 Nov 30;10.1093/pm/pny217.

Lembke A, Ottestad E, Schmiesing C. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period. *Pain Med.* 2019 Mar 1;20(3):425-428.

Silva MJ, Rubinstein A. Continuous Perioperative Sublingual Buprenorphine. *J Pain Palliat Care Pharmacother.* 2016 Dec;30(4):289-293.

Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy. *Anesthesiol Clin.* 2018 Sep;36(3):345-359.

Pain in Abstinent/Recovered OUD Patients (Q43)

Voikow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. *Longo DL, ed. N Engl J Med.* 2016;374(4):363-371.

Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. *Addiction.* 2007;102(5):752-760.

Ward EN, Quaye AN-A, Wilens TE. Opioid Use Disorders: Perioperative Management of a Special Population. *Anesth Analg.* 2018;127(2):539-547.

Vlok R, An GH, Binks M, Melhuish T, White L. Sublingual buprenorphine versus intravenous or intramuscular morphine in acute pain: A systematic review and meta-analysis of randomized control trials. *Am J Emerg Med.* 2019 Mar;37(3):381-386.

Cheatle MD, Savage SR. Informed consent in opioid therapy: a potential obligation and opportunity. *J Pain Symptom Manage.* 2012;44(1):105-116.

ED Management of Chronic Pain (Q44, Q45)

Centers for Disease Control. Guidelines for Prescribing Opioids for chronic pain. https://www.cdc.gov/drugoverdose/pdf/Guidelines_Factsheet-a.pdf. Accessed July 24, 2019.

American Academy of Emergency Medicine, 2013. Emergency Department Opioid Prescribing Guidelines for the Treatment of Non-Cancer Related Pain. Available at: <https://www.aaem.org/UserFiles/file/Emergency-Department-Opioid-Prescribing-Guidelines.pdf> Accessed on January 14, 2019.

Motov S, Strayer R, Hayes BD, Reiter M, Rosenbaum S, Richman M, Repanshek Z, Taylor S, Friedman B, Vilke G, Lasoff D. The Treatment of Acute Pain in the Emergency Department: A White Paper Position Statement Prepared for the American Academy of Emergency Medicine. *J Emerg Med.* 2018 May;54(5):731-736.

Cantrill SV, Brown MD, Carlisle RJ, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. *Ann Emerg Med.* 2012;60(4):499-525.

Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *MMWR Recomm Rep.* 2016;65(1):1-49.

Yi P, Prybylkowski P. Opioid Induced Hyperalgesia. *Pain Med.* 2015;16 Suppl 1:S32-6.

Juurlink DN, Dhalla IA. Dependence and addiction during chronic opioid therapy. *J Med Toxicol.* 2012;8(4):393-9.

Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—guidance. *Pain Physician.* 2012;15(3 Suppl):S67-116.

Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 1—evidence assessment. *Pain Physician.* 2012;15(3 Suppl):S1-65.

Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatso C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med.* 2015 Feb 17;162(4):276-86.

Busse JW, Wang L, Kamaleldin M, Craigie S, et al. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. *JAMA*. 2018 Dec 18;320(23):2448-2460.

Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med*. 2017 Apr 4;166(7):514-530.

American College of Emergency Physicians. Palliative Care Toolkit for EM Providers. Available at: <https://www.acep.org/how-we-serve/sections/palliative-medicine/news/april-2015/palliative-care-toolkit-for-em-providers/#sm.00001rdk18f4gctluhfevziz7b0>. Accessed on January 14, 2019.

Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of under-treatment in cancer pain. A review of published literature. *Ann Oncol*. 2008;19(12):1985–1991.

DeSandre P, Chandrasekaran E, 2018. Pain at the End of Life 2018. Available at: <http://painandpsa.org/endoflife>. Accessed July 24, 2019.

Methadone in the ED (Q46, Q47)

Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus SM, Mehta D, Meyer MC, Portenoy R, Savage S, Strain E, Walsh S, Zeltzer L; American Pain Society; Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain*. 2014 Apr;15(4):321-37.

Faul M, Bohm M, Alexander C. Methadone Prescribing and Overdose and the Association with Medicaid Preferred Drug List Policies - United States, 2007-2014. *MMWR Morb Mortal Wkly Rep*. 2017 Mar 31; 66(12):320-323.

Su MK, Lopez JH, Crossa A, Hoffman RS. Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome. *Am J Emerg Med*. 2018 Nov;36(11):1951-1956.

Nudging Providers to Best Practice (Q48)

Michael SS, Babu KM, Androski C Jr, Reznick MA. Effect of a Data-driven Intervention on Opioid Prescribing Intensity Among Emergency Department Providers: A Randomized Controlled Trial. *Acad Emerg Med*. 2018 May;25(5):482-493.

Boyle KL, Cary C, Dizitzer Y, Novack V, Jagminas L, Smulowitz PB. Reduction of opioid prescribing through the sharing of individual physician opioid prescribing practices. *Am J Emerg Med*. 2019 Jan;37(1):118-122.

Burton JH, Hoppe JA, Echternach JM, Rodgers JM, Donato M. Quality Improvement Initiative to Decrease Variability of Emergency Physician Opioid Analgesic Prescribing. *West J Emerg Med*. 2016 May;17(3):258-63.

Friedman FD, Mostofi MB, Barnewolt BA. Transparency as a Tool to Reduce Opioid Prescribing in One Emergency Department. *Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health*. 2017;18(6.1).

Weiner SG, Baker O, Poon SJ, Rodgers AF, Garner C, Nelson LS, Schuur JD. The Effect of Opioid Prescribing Guidelines on Prescriptions by Emergency Physicians in Ohio. *Ann Emerg Med*. 2017 Dec;70(6):799-808.e1.

Fox TR, Li J, Stevens S, Tippie T. A performance improvement prescribing guideline reduces opioid prescriptions for emergency department dental pain patients. *Ann Emerg Med*. 2013 Sep;62(3):237-40.

Beaudoin FL, Janicki A, Zhai W, Choo EK. Trends in opioid prescribing before and after implementation of an emergency department opioid prescribing policy. *Am J Emerg Med*. 2018 Feb;36(2):329-331.

Chacko J, Greenstein J, Ardolic B, Berwald N. Effect of an emergency department opioid prescription policy on prescribing patterns. *Am J Emerg Med*. 2017 Sep;35(9):1327-1329.

del Portal DA, Healy ME, Satz WA, McNamara RM. Impact of an Opioid Prescribing Guideline in the Acute Care Setting. *J Emerg Med*. 2016 Jan;50(1):21-7.

Kahler ZP, Musey PI, Schaffer JT, Johnson AN, Strachan CC, Shufflebarger CM. Effect Of A "No Superuser Opioid Prescription" Policy On ED Visits And Statewide Opioid Prescription. *West J Emerg Med*. 2017 Aug;18(5):894-902.

Olsen JC, Ogarek JL, Goldenberg EJ, Sulo S. Impact of a Chronic Pain Protocol on Emergency Department Utilization. *Acad Emerg Med*. 2016 Apr;23(4):424-32.

Osborn SR, Yu J, Williams B, Vasilyadis M, Blackmore CC. Changes in Provider Prescribing Patterns After Implementation of an Emergency Department Prescription Opioid Policy. *J Emerg Med*. 2017 Apr; 52(4):538-546.

Cantrill SV, Brown MD, Carlisle RJ, Delaney KA, Hays DP, Nelson LS, O'Connor RE, Papa A, Sporer KA, Todd KH, Whitson RR; American College of Emergency Physicians Opioid Guideline Writing Panel. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. *Ann Emerg Med*. 2012 Oct;60(4):499-525.

Motov S, Strayer R, Hayes BD, Reiter M, Rosenbaum S, Richman M, Repanshek Z, Taylor S, Friedman B, Vilke G, Lasoff D. The Treatment of Acute Pain in the Emergency Department: A White Paper Position Statement Prepared for the American Academy of Emergency Medicine. *J Emerg Med*. 2018 May;54(5):731-736.

Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioid therapy and chronic noncancer pain. *CMAJ*. 2017 May 8;189(18):E659-E666.

Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the Safety of Opioid Use for Acute Noncancer Pain in Hospitalized Adults: A Consensus Statement From the Society of Hospital Medicine. *J Hosp Med*. 2018 Apr;13(4):263-271.

Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *JAMA*. 2016 Apr 19;315(15):1624-45.

Nagel FW, Kattan JA, Mantha S, Nelson LS, Kunins HV, Paone D. Promoting Health Department Opioid-Prescribing Guidelines for New York City Emergency Departments: A Qualitative Evaluation. *J Public Health Manag Pract*. 2018 Jul/Aug;24(4):306-309.

Kilaru AS, Gadsden SM, Perrone J, Paciotti B, Barg FK, Meisel ZF. How do physicians adopt and apply opioid prescription guidelines in the emergency department? A qualitative study. *Ann Emerg Med*. 2014 Nov;64(5):482-489.e1.

Meecker D, Knight TK, Friedberg MW, Linder JA, Goldstein NJ, Fox CR, Rothfeld A, Diaz G, Doctor JN. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. *JAMA Intern Med*. 2014 Mar;174(3):425-31.

Delgado MK, Shofer FS, Patel MS, Halpern S, Edwards C, Meisel ZF, Perrone J. Association between Electronic Medical Record Implementation of Default Opioid Prescription Quantities and Prescribing Behavior in Two Emergency Departments. *J Gen Intern Med*. 2018 Apr;33(4):409-411.

Chiu AS, Jean RA, Hoag JR, Freedman-Weiss M, Healy JM, Pei KY. Association of Lowering Default Pill Counts in Electronic Medical Record Systems With Postoperative Opioid Prescribing. *JAMA Surg*. 2018 Nov 1;153(11):1012-1019.

Weiner SG, Price CN, Atalay AJ, Harry EM, Pabo EA, Patel R, Suzuki J, Anderson S, Ashley SW, Kachalia A. A Health System-Wide Initiative to Decrease Opioid-Related Morbidity and Mortality. *Jt Comm J Qual Patient Saf.* 2019 Jan;45(1):3-13.

ACEP Now, 2014. ED Waiting Room Posters on Prescribing Pain Medications May Violate EMTALA. Available at: <https://www.acepnow.com/article/ed-waiting-room-posters-prescribing-pain-medications-may-violate-emtala>. Accessed July 24, 2019.

Weiner SG, Yannopoulos PF, Lu C. Chronic Pain Patients' Impressions of an Emergency Department Opioid Prescribing Guideline Poster. *Pain Med.* 2015 Sep;16(9):1759-63.

Conclusion

Rubin R. As Overdoses Climb, Emergency Departments Begin Treating Opioid Use Disorder. *JAMA.* 2018 Jun 5;319(21):2158-2160.

Duber HC, Barata IA, Cioè-Peña E, Liang SY, Ketcham E, Macias-Konstantopoulos W, Ryan SA, Stavros M, Whiteside LK. Identification, Management, and Transition of Care for Patients With Opioid Use Disorder in the Emergency Department. *Ann Emerg Med.* 2018 Oct;72(4):420-431.

Hu T, Snider-Adler M, Nijmeh L, Pyle A. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers. *CJEM.* 2019 Apr 22:1-7.

Ahmadi J, Jahromi MS, Ghahremani D, London ED. Single high-dose buprenorphine for opioid craving during withdrawal. *Trials.* 2018 Dec 10;19(1):675.

Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series. *Am J Addict.* 2019 Jul;28(4):262-265.

Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dürsteler KM, Vogel M. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. *Subst Abuse Rehabil.* 2016 Jul 20;7:99-105.

Coe MA, Lofwall MR, Walsh SL. Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. *J Addict Med.* 2019 Mar/Apr;13(2):93-103.

Goodnough A. This ER Treats Opioid Addiction on Demand. That's Very Rare. *The New York Times.* 2018.

Rapoport AB, Rowley CF. Stretching the Scope - Becoming Frontline Addiction-Medicine Providers. *N Engl J Med.* 2017 Aug 24;377(8):705-707.